Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,409 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03889275 | A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors | completed | Phase 1 | 39 | MedImmune LLCINDUSTRY | 2 | Feb 21, 2023 | clinicaltrials |
| NCT03063762 | Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | completed | Phase 1 | 69 | Hoffmann-La RocheINDUSTRY | 9 | Feb 17, 2023 |
| NCT01146756 | MEK Inhibitor and Thoracic Radiotherapy Trial(MEKRT) | completed | Phase 1 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT02000934 | A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies | completed | Phase 1 | 143 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 41 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT04592484 | A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors | completed | Phase 1 / Phase 2 | 27 | Codiak BioSciencesINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT01625286 | Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients(BEECH) | completed | Phase 1 / Phase 2 | 148 | AstraZenecaINDUSTRY | 11 | Jan 18, 2023 | clinicaltrials |
| NCT02890069 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | completed | Phase 1 | 298 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 11, 2023 | clinicaltrials |
| NCT05551897 | A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole | completed | Phase 1 | 14 | AstraZenecaINDUSTRY | 1 | Jan 6, 2023 | clinicaltrials |
| NCT01812603 | A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 6 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT01812616 | A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients | completed | Phase 1 / Phase 2 | 21 | Jazz PharmaceuticalsINDUSTRY | 2 | Dec 20, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT02627274 | A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 9 | Nov 22, 2022 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT02257567 | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 331 | Hoffmann-La RocheINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT01977638 | Phase 1 Trial of CXD101 in Patients With Advanced Cancer | completed | Phase 1 | 51 | Oxford University Hospitals NHS TrustOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02285179 | Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen(Poseidon) | completed | Phase 1 / Phase 2 | 189 | The Netherlands Cancer InstituteOTHER | 4 | Oct 12, 2022 | clinicaltrials |
| NCT03868228 | PIPAC for the Treatment of Colorectal Peritoneal Metastases | unknown | Phase 1 / Phase 2 | 30 | Imperial College LondonOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02588105 | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer(AToM) | completed | Phase 1 | 84 | AstraZenecaINDUSTRY | 4 | Sep 19, 2022 | clinicaltrials |
| NCT02639546 | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors(iMATRIXcobi) | completed | Phase 1 / Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 7 | Sep 16, 2022 | clinicaltrials |
| NCT05008913 | Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib(ADME) | terminated | Phase 1 | 2 | AstraZenecaINDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT04949425 | A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours | terminated | Phase 1 | 3 | AstraZenecaINDUSTRY | 2 | Sep 2, 2022 | clinicaltrials |
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | terminated | Phase 1 | 2 | Codiak BioSciencesINDUSTRY | 1 | Sep 2, 2022 | clinicaltrials |
| NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma(CAPER) | unknown | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT01791985 | AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)(RADICAL) | completed | Phase 1 / Phase 2 | 52 | Imperial College LondonOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02341625 | A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 126 | Bristol-Myers SquibbINDUSTRY | 7 | Aug 18, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03527147 | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)(PRISM) | completed | Phase 1 | 30 | Acerta Pharma BVINDUSTRY | 2 | Aug 15, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT03150056 | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer | terminated | Phase 1 | 73 | GlaxoSmithKlineINDUSTRY | 4 | Aug 10, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT02316171 | CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)(CANON) | completed | Phase 1 | 16 | ViralyticsINDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT01827579 | Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)(ICAT) | completed | Phase 1 / Phase 2 | 37 | University College, LondonOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT03102320 | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors(ARCS-Multi) | completed | Phase 1 | 173 | BayerINDUSTRY | 12 | Jun 30, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | completed | Phase 1 | 250 | Blueprint Medicines CorporationINDUSTRY | 10 | Jun 21, 2022 | clinicaltrials |
| NCT01884922 | Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults(VINILO) | completed | Phase 1 | 35 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 8 | May 27, 2022 | clinicaltrials |
| NCT03141203 | Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients(RomiCar) | completed | Phase 1 / Phase 2 | 50 | University of BirminghamOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT04727138 | 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546 | completed | Phase 1 | 64 | Exscientia AI LimitedINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT02659020 | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma(ANNOUNCE 2) | completed | Phase 1 / Phase 2 | 310 | Eli Lilly and CompanyINDUSTRY | 10 | May 9, 2022 | clinicaltrials |
| NCT02121639 | Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy(ProCAID) | completed | Phase 1 / Phase 2 | 160 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02343120 | Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 385 | BeiGeneINDUSTRY | 6 | Apr 28, 2022 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials